Standout Papers

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BF... 2017 2026 2020 2023 311
  1. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017)
    Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology

Immediate Impact

2 from Science/Nature 51 standout
Sub-graph 1 of 22

Citing Papers

Recent Advances in 3D Printing of Smart Scaffolds for Bone Tissue Engineering and Regeneration
2024 Standout
Cell death
2024 Standout
2 intermediate papers

Works of Iryna Dyagil being referenced

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
2015

Author Peers

Author Last Decade Papers Cites
Iryna Dyagil 687 719 137 317 55 1.3k
W. Queißer 534 716 121 265 111 1.4k
Aaron Weitzman 557 670 64 414 37 1.2k
Philippe Mineur 620 612 219 161 49 1.4k
Ferdinando Frigeri 468 411 427 153 60 1.1k
P Stryckmans 488 553 210 89 55 1.1k
Joanna Góra‐Tybor 702 562 372 179 74 1.1k
Canellos Gp 420 521 503 126 50 1.3k
Farhad Ravandi‐Kashani 572 652 310 160 95 1.4k
Xenophon Yataganas 362 696 91 80 74 1.5k
Saengsuree Jootar 896 1143 95 506 74 1.5k

All Works

Loading papers...

Rankless by CCL
2026